Our innovative research has resulted in the discovery of truly disruptive technologies

Immune Regulation’s collaboration with eminent researchers at two leading British universities, King’s College, London and St George’s University, London, is the foundation stone of our work.

Our innovative research has resulted in the discovery of truly disruptive technologies addressing unmet needs in the significant respiratory and rheumatoid arthritis markets. Immune Regulation: resetting expectations

Our two lead candidates, PIN201104 (‘1104) and IRL201805 (‘1805) are first-in-class compounds derived from endogenous immuno-regulatory proteins (mTB chaperonin and BiP).

 

‘1104 and ‘1805 appear to modulate key cells of the immune system that control the inflammatory response, with a long duration of action following a single dose (‘1104, 14 days; ‘1805, up to 12 weeks) despite their short pharmacokinetic half-life. They are not immunosuppressants and have no impact on the body’s ability to fight infection. Rather, they are immunomodulators: they appear to reset the immune response with the potential for inducing long-term disease remission.

PIN201104 (‘1104)

A potential first-in-class immune resetting drug for asthma and other inflammatory diseases with the potential to modify the course of immuno-inflammatory disease with a short-term drug exposure leading to long-term disease remission, providing a broad spectrum of activity (allergen agnostic), and a benign safety profile.

Click here to find out more.

IRL201805 (‘1805)

A BiP analogue for rheumatoid arthritis with Orphan Drug potential in rare diseases offering a reduction in inflammation and autoimmune response in patients with rheumatoid arthritis up to 12 weeks following a single dose, a reduction in osteoclast activity’ and a clean safety profile.

Click here to find out more.

Immune Regulation: advancing the control and management of moderate-to-severe chronic inflammatory diseases.